In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Hepatitis A is a very contagious liver infection that is common in many parts of the world. Here's more about the vaccine for babies and kids.

The hepatitis B vaccine is one of the very first vaccines your baby will get before she leaves the hospital. This vaccine protects her from a dangerous (but preventable!) liver infection and is given ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Hong Kong health authorities have apologised for mistakenly giving pneumococcal vaccines to two children at a health centre ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...

"We were delighted to discover not only important details about the mechanisms of HBV gene regulation, but also a promising ...